Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the ivan study

Ophthalmology

Volumn 120, Issue 12, 2013, Pages 2637-2643

  Lotery, Andrew J ^a   Gibson, Jane ^a   Cree, Angela J ^a   Downes, Susan M ^b   Harding, Simon P ^c   Rogers, Chris A ^d   Reeves, Barnaby C ^d   Ennis, Sarah ^a   Chakravarthy, Usha ^e  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b OXFORD EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ARMS2 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; FRIZZLED PROTEIN; FZD4 PROTEIN, HUMAN; HTRA1 PROTEIN, HUMAN; PROTEIN; SERINE PROTEINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CHROMOSOME 2; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE REPLICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; GENE FREQUENCY; GENETICS; GENOTYPING TECHNIQUE; INTRAVITREAL DRUG ADMINISTRATION; PHYSIOLOGY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; COMPLEMENT FACTOR H; FEMALE; FRIZZLED RECEPTORS; GENE FREQUENCY; GENOTYPING TECHNIQUES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; SERINE ENDOPEPTIDASES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84887989386     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.07.046     Document Type: Article

References (23)

1. J. Ambati, B.K. Ambati, and S.H. Yoo Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies Surv Ophthalmol 48 2003 257 293
2. P.J. Rosenfeld, D.M. Brown, and J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. D.M. Brown, P.K. Kaiser, and M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
4. S.F. Grant, and H. Hakonarson Recent development in pharmacogenomics: from candidate genes to genome-wide association studies Expert Rev Mol Diagn 7 2007 371 393
5. R. Rosell, T. Moran, and C. Queralt Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
6. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
7. S.V. Goverdhan, S. Hannan, and R.B. Newsom An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment Eye (Lond) 22 2008 849 854
8. M.A. Brantley Jr., A.M. Fang, and J.M. King Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2007 2168 2173
9. A.Y. Lee, A.K. Raya, and S.M. Kymes Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 93 2009 610 613
10. M.L. Klein, P.J. Francis, and B. Rosner CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration Ophthalmology 115 2008 1019 1025
11. R.M. Rohan, A. Fernadez, and T. Udagawa Genetic heterogeneity of angiogenesis in mice FASEB J 14 2000 871 876
12. K. Nakai, M.S. Rogers, and T. Baba Genetic loci that control the size of laser-induced choroidal neovascularization FASEB J 23 2009 2235 2243
13. IVAN Study Investigators U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
14. S. Ennis, J. Gibson, and H. Griffiths Prevalence of myocilin gene mutations in a novel UK cohort of POAG patients Eye (Lond) 24 2010 328 333
15. B. Kloeckener-Gruissem, D. Barthelmes, and S. Labs Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4694 4702
16. S.J. Teper, A. Nowinska, and J. Pilat Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration Mol Vis [serial online] 16 2010 2598 2604 Available at: http://www.molvis.org/molvis/v16/a278/ Accessed July 12, 2013
17. H. Tian, S.L. McKnight, and D.W. Russell Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells Genes Dev 11 1997 72 82
18. K. Ding, M. Scortegagna, and R. Seaman Retinal disease in mice lacking hypoxia-inducible transcription factor-2alpha Invest Ophthalmol Vis Sci 46 2005 1010 1016
19. -/- mice Nat Genet 35 2003 331 340
20. S.A. Hagstrom, G.S. Ying, and G.J. Pauer Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 120 2013 593 599
21. Diabetic Retinopathy Clinical Research Network Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema Ophthalmology 114 2007 525 536
22. N. Doris, P.M. Hart, and U. Chakravarthy Relation between macular morphology and visual function in patients with choroidal neovascularisation of age related macular degeneration Br J Ophthalmol 85 2001 184 188
23. T. Moutray, M. Alarbi, and G. Mahon Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation Br J Ophthalmol 92 2008 361 364